Semaglutide linked to 26% lower 5-year predicted dementia risk

A new study analyzing real-world data suggests that semaglutide, a popular GLP-1 receptor agonist used for type 2 diabetes and obesity, may reduce the 5-year predicted risk of dementia by 26% compared to other diabetes medications. The research, published in Alzheimer's & Dementia, adds to growing evidence that this class of drugs could have neuroprotective effects, potentially opening new avenues for dementia prevention.